Business Wire

Cybersecurity : IKOULA Adds ESET Solutions to Its Offer, to Strengthen Data Protection for Companies

14.9.2022 18:11:00 EEST | Business Wire | Press release

Share

With the resurgence of cyber-attacks, which are ever more violent and paralyzing for companies, IKOULA - a leading player in the IaaS (Infrastructure As A Service), dedicated servers and outsourcing market - is joining forces with ESET – a global leader in digital security – to offer companies a professional endpoint protection solution against ransomware and zero-day threats.

At a time when cyber-risks must be approached in the same way as all other business risks, IKOULA is strengthening its range of cyber-protection solutions, and now offers to its customers the ESET solution: a solution created to protect all company's workstations from a single interface, whether they are desktop computers, laptops, or mobile devices.

"At ESET, we have made the choice to include in our solutions not only Cloud sandboxing technology – that is to say blocking ransomware and zero-day threats - but also full disk encryption functionality, as well as advanced multi-layer technology", explains Bruno BONNY, Marketing Director of ESET France. “Protection against cyber-attacks is therefore comprehensive and optimal. »

"Companies' cybersecurity needs are constantly increasing", continues Jean-Pascal MACCHI, Managing Director of IKOULA. “By offering our customers ESET solution, we give them the keys to responding to these issues and protecting themselves against the risks that could affect their dedicated servers, but also their other devices, and by extension their activity. »

About IKOULA

Pioneer of Cloud Computing since 1998, IKOULA has its own Datacenters in France, as well as two subsidiaries, in Spain and the Netherlands. Placing people at the heart of its activity, IKOULA maintains a close relationship with its customers, and provides them with teams of experts available 24/7, to advise and support them in the choice of professional IT solutions.
Web hosting, cybersecurity, managed services, Cloud computing or even unified communication thanks to the support of its parent company SEWAN, everything is done to meet the needs of today's and tomorrow's businesses.

About ESET

For more than 30 years, ESET® has been providing enterprises across the globe with industry-leading IT security software and services, including endpoint detection and response, encryption and authentication, and comprehensive security services packages. With high-performing, easy-to-use solutions that cater to businesses of all sizes, ESET protects customers from increasingly sophisticated digital threats in an ever-evolving landscape. ESET delivers to the enterprise market the people, expertise, and cutting-edge technology required to keep businesses safe and running without interruption.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Laurane VASSOR ARCARO
lvassorarcaro@ikoula.com
+33 1 84 01 02 69

Darina SANTAMARIA
darina.j@eset-nod32.fr
+33 01 55 89 08 88

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye